Evogene Ltd.
EVGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $312 | $884 | $2,444 | $1,611 |
| % Growth | -64.7% | -63.8% | 51.7% | – |
| Cost of Goods Sold | $438 | $426 | $2,193 | $1,348 |
| Gross Profit | -$126 | $458 | $251 | $263 |
| % Margin | -40.4% | 51.8% | 10.3% | 16.3% |
| R&D Expenses | $1,094 | $2,031 | $2,629 | $2,808 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,495 | $1,498 | $1,939 | $2,022 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,589 | $3,529 | $4,568 | $4,830 |
| Operating Income | -$2,715 | -$3,071 | -$4,317 | -$4,567 |
| % Margin | -870.2% | -347.4% | -176.6% | -283.5% |
| Other Income/Exp. Net | -$13 | -$457 | $1,328 | $4,569 |
| Pre-Tax Income | -$2,728 | -$3,528 | -$2,989 | $2 |
| Tax Expense | $1 | $1 | $0 | $7 |
| Net Income | $3,874 | -$4,462 | -$2,587 | $427 |
| % Margin | 1,241.7% | -504.8% | -105.9% | 26.5% |
| EPS | 0.44 | -0.62 | -0.38 | 0.063 |
| % Growth | 171% | -63.2% | -705.1% | – |
| EPS Diluted | 0.44 | -0.62 | -0.38 | 0.063 |
| Weighted Avg Shares Out | 8,716 | 7,226 | 6,798 | 6,796 |
| Weighted Avg Shares Out Dil | 8,716 | 7,226 | 6,798 | 6,796 |
| Supplemental Information | – | – | – | – |
| Interest Income | $465 | $235 | $1,603 | $4,726 |
| Interest Expense | $453 | $628 | $464 | $144 |
| Depreciation & Amortization | $281 | $290 | $579 | $593 |
| EBITDA | -$1,978 | -$2,546 | -$1,944 | $752 |
| % Margin | -634% | -288% | -79.5% | 46.7% |